Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 May 15;20(6):632–642. doi: 10.1016/j.neo.2018.04.004

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 The Authors

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Fig. 5 — Influence of expression of CD20, CD25, CD33 and CD52 on LSCs on survival in ALL patients

The probability of overall survival (OS) in patients with ALL (n = 49) was determined for subgroups of patients in whom CD34⁺/CD38⁻ stem cells either expressed (pos) or did not express (neg) substantial levels of CD20, CD25, CD33 or CD52. Expressers (pos) were defined as a median fluorescence intensity (MFI) of ≥3 and low expressers (neg) as a MFI of <3. The median follow-up of our ALL patients was 623 days. The probability of OS was calculated by the product limit method of Kaplan and Meier.